Association of Ki-67 Change Pattern After Core Needle Biopsy and Prognosis in HR+/HER2- Early Breast Cancer Patients

被引:4
|
作者
Li, Shuai [1 ]
Chen, Xiaosong [1 ]
Shen, Kunwei [1 ]
机构
[1] Shanghai Jiao Tong Univ, Ruijin Hosp, Comprehens Breast Hlth Ctr, Dept Gen Surg,Sch Med, Shanghai, Peoples R China
来源
FRONTIERS IN SURGERY | 2022年 / 9卷
基金
中国国家自然科学基金;
关键词
breast neoplasms; core needle biopsy; surgical sample; Ki-67; change; prognosis; INTERNATIONAL EXPERT CONSENSUS; HER2; STATUS; SURGICAL SPECIMENS; ESTROGEN-RECEPTOR; ENDOCRINE THERAPY; AMERICAN SOCIETY; KI67; EXPRESSION; WOMEN; INDEX; EXCISION;
D O I
10.3389/fsurg.2022.905575
中图分类号
R61 [外科手术学];
学科分类号
摘要
Background; To investigate the association of Ki-67 change pattern after core needle biopsy (CNB) and prognosis in HR+/HER2- early breast cancer patients. Method: Eligible patients were categorized into three groups: Low group, Elevation group, and High group. Chi-square test and logistic regression analysis were used to compare the clinic-pathological characteristics. Kaplan-Meier method was used to estimate the rates of recurrence-free interval (RFI) and breast cancer-specific survival (BCSS), which were compared via the Log-rank test. Cox proportional hazard analysis was performed to investigate independent prognostic factors. Results: A total of 2,858 patients were included: 1,179 (41.3%), 482 (16.9%), and 1,197 (41.8%) patients were classified into the low, elevation, and high groups, respectively. Age, tumor size, histological grade, lymph-vascular invasion (LVI), and ER level status were associated with Ki-67 change pattern after CNB. With a median follow-up of 53.6 months, the estimated 5-year RFI rates for the low group, elevation, and high groups were 96.4%, 95.3% and 90.9%, respectively (P < 0.001). And 5-year BCSS rates were 99.3%, 98.3% and 96.8%, respectively (P = 0.001). Compared with patients in the low group, patients in the high group had significantly worse RFI (hazard ratio [HR] 1.71, 95% confidence interval [CI] 1.16-2.54) in multivariate analysis. Conclusions: Ki-67 change after CNB was associated with prognosis in HR+/HER2- early breast cancer. Patients with Ki-67 high or elevation after CNB had an inferior disease outcome, indicating the necessity of re-evaluating Ki-67 on surgical specimens after CNB.
引用
收藏
页数:9
相关论文
共 50 条
  • [1] Surgery time interval and molecular subtype may influence Ki67 change after core needle biopsy in breast cancer patients
    Chen, Xiaosong
    Zhu, Siji
    Fei, Xiaochun
    Garfield, David H.
    Wu, Jiayi
    Huang, Ou
    Li, Yafen
    Zhu, Li
    He, Jianrong
    Chen, Weiguo
    Jin, Xiaolong
    Shen, Kunwei
    BMC CANCER, 2015, 15
  • [2] The Role of Ki-67 in HR+/HER2-Breast Cancer: A Real-World Study of 956 Patients
    Ma, Qin
    Liu, Yao-Bang
    She, Tong
    Liu, Xin-Lan
    BREAST CANCER-TARGETS AND THERAPY, 2024, 16 : 117 - 126
  • [3] The Reliability of Core-Needle Biopsy in Assessment of Hormone Receptor, HER2, and Ki-67 in Breast Carcinoma
    Ueno, Nozomi
    Kuroda, Hajime
    Abe, Akihito
    Kubota, Keiichi
    Kato, Hiroyuki
    Imai, Yasuo
    INTERNATIONAL SURGERY, 2017, 102 (11-12) : 522 - 529
  • [4] Population-based estimate for the correlation of the Oncotype Dx Breast Recurrence Score® result and Ki-67 IHC MIB-1 pharmDx in HR+, HER2-, node-positive early breast cancer
    Crager, Michael
    Wijayawardana, Sameera R.
    Gruver, Aaron M.
    Blacklock, Andrea
    Russell, Christy
    Baehner, Frederick L.
    Sapunar, Francisco
    BREAST CANCER RESEARCH, 2022, 24 (01)
  • [5] Ki67 increase after core needle biopsy associated with worse disease outcome in HER2-negative breast cancer patients
    Tong, Yiwei
    Dai, Jiangfeng
    Huang, Jiahui
    Fei, Xiaochun
    Shen, Kunwei
    Liu, Qingmeng
    Chen, Xiaosong
    SCIENTIFIC REPORTS, 2023, 13 (01)
  • [6] Concordance between core needle biopsy and surgical excision specimens for Ki-67 in breast cancer - a systematic review of the literature
    Kalvala, Jahnavi
    Parks, Ruth M.
    Green, Andrew R.
    Cheung, Kwok-Leung
    HISTOPATHOLOGY, 2022, 80 (03) : 468 - 484
  • [7] Use of the gene expression test Prosigna® in premenopausal patients with HR+, HER2-early breast cancer: Correlation of the results with the proliferation marker Ki-67
    Ziegler, Cordula
    Sotlar, Karl
    Hofmann, Daniel Maria
    Kolben, Thomas
    Harbeck, Nadia
    Wuerstlein, Rachel
    BREAST CARE, 2024, 19 (01) : 34 - 42
  • [8] A real-world retrospective study of the use of Ki-67 testing and treatment patterns in patients with HR+, HER2-early breast cancer in the United States
    Brown, Jacqueline
    Scardo, Savannah
    Method, Michael
    Schlauch, Dan
    Misch, Amanda
    Picard, Shaita
    Hamilton, Erika
    Jones, Suzanne
    Burris, Howard
    Spigel, David
    BMC CANCER, 2022, 22 (01)
  • [9] Prognostic effect of Ki-67 in common clinical subgroups of patients with HER2-negative, hormone receptor-positive early breast cancer
    Fasching, Peter A.
    Gass, Paul
    Haeberle, Lothar
    Volz, Bernhard
    Hein, Alexander
    Hack, Carolin C.
    Lux, Michael P.
    Jud, Sebastian M.
    Hartmann, Arndt
    Beckmann, Matthias W.
    Slamon, Dennis J.
    Erber, Ramona
    BREAST CANCER RESEARCH AND TREATMENT, 2019, 175 (03) : 617 - 625
  • [10] A real-world retrospective study of the use of Ki-67 testing and treatment patterns in patients with HR+, HER2− early breast cancer in the United States
    Jacqueline Brown
    Savannah Scardo
    Michael Method
    Dan Schlauch
    Amanda Misch
    Shaita Picard
    Erika Hamilton
    Suzanne Jones
    Howard Burris
    David Spigel
    BMC Cancer, 22